Trelegy Ellipta (GlaxoSmithKline LLC)
Welcome to the PulseAid listing for the Trelegy Ellipta drug offered from GlaxoSmithKline LLC. This Corticosteroid [EPC],Corticosteroid Hormone Receptor Agonists [MoA],Anticholinergic [EPC],Cholinergic Antagonists [MoA],Adrenergic beta2-Agonists [MoA],beta2-Adrenergic Agonist [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | GlaxoSmithKline LLC |
| NON-PROPRIETARY NAME: | fluticasone furoate, umeclidinium bromide and vilanterol trifenatate |
| SUBSTANCE NAME: | FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Corticosteroid [EPC],Corticosteroid Hormone Receptor Agonists [MoA],Anticholinergic [EPC],Cholinergic Antagonists [MoA],Adrenergic beta2-Agonists [MoA],beta2-Adrenergic Agonist [EPC] |
| ROUTE: | RESPIRATORY (INHALATION) |
| DOSAGE FORM: | POWDER |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2017-09-18 |
| END MARKETING DATE: | 0000-00-00 |
Trelegy Ellipta HUMAN PRESCRIPTION DRUG Details:
| Item Description | Trelegy Ellipta from GlaxoSmithKline LLC |
| LABELER NAME: | GlaxoSmithKline LLC |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 100; 62.5; 25(ug/1; ug/1; ug/1) |
| START MARKETING DATE: | 2017-09-18 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0173-0887_c550bb69-ea8e-4ff6-9b45-7c99e3eaad1b |
| PRODUCT NDC: | 0173-0887 |
| APPLICATION NUMBER: | NDA209482 |
Other FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE Pharmaceutical Manufacturers / Labelers:
